GFM
AXSM icon

GF Fund Management’s Axsome Therapeutics AXSM Stock Holding History

GF Fund Management’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$192K Buy
1,133
+143
+14% +$24.7K ﹤0.01% 287
2025
Q4 		$181K Sell
990
-84
-8% -$11.7K ﹤0.01% 305
2025
Q3 		$130K Sell
1,074
-167
-13% -$18.8K ﹤0.01% 320
2025
Q2 		$130K Hold
1,241
– – ﹤0.01% 349
2025
Q1 		$145K Buy
1,241
+223
+22% +$25.4K ﹤0.01% 341
2024
Q4 		$86.1K Buy
+1,018
New +$93.6K ﹤0.01% 338

Other funds holding AXSM

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

GF Fund Management's AXSM Position: Q1 2026 in Review

GF Fund Management increased its Axsome Therapeutics (AXSM) stake by 14% in Q1 2026, buying an estimated $24.7K and bringing the position to 1,133 shares worth $192K. The position accounts for ﹤0.01% of the portfolio, ranked #287.

GF Fund Management first reported a position in AXSM in Q4 2024 and has held it in 6 quarters since. 409 funds tracked by Wall St. Rank hold AXSM as of Q1 2026.

  • GF Fund Management held 1,133 shares of Axsome Therapeutics worth $192K as of Q1 2026.
  • GF Fund Management bought 143 Axsome Therapeutics shares in Q1 2026, an estimated $24.7K.
  • Axsome Therapeutics made up ﹤0.01% of GF Fund Management's portfolio in Q1 2026, its #287 holding.
  • GF Fund Management first reported a position in Axsome Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 409 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2026.

Based on GF Fund Management's 13F filing for Q1 2026, filed 15 Apr 2026.